Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,971.00
Bid: 1,971.00
Ask: 1,972.00
Change: -29.00 (-1.45%)
Spread: 1.00 (0.051%)
Open: 2,008.00
High: 2,012.00
Low: 1,958.00
Prev. Close: 2,000.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Friday broker round-up UPDATE

Fri, 01st Aug 2014 10:33

AstraZeneca: Deutsche Bank ups target price from 3950p to 4000p staying with its hold recommendation.Avacta: Numis places both its target price and its buy recommendation under review.Barclays: Berenberg upgrades from sell to hold with a target price of 220p.Bodycote: UBS shifts target price from 860p to 865p and maintains a buy recommendation.Breedon: Berenberg initiates with a target price of 50p and a buy recommendation.Capita: Credit Suisse lowers target price from 1250p to 1215p and downgrades from outperform to neutral.Computacenter: Jefferies cuts target price from 720p to 690p retaining a hold recommendation.CVS Group: Berenberg starts with a target price of 410p and a buy recommendation.Daily Mail & General Trust: Numis shifts target price from 1180p to 1185p and stays with its buy recommendation.Diageo: Canaccord Genuity reduces target price from 1835p to 1540p downgrading from hold to sell.Dignity: Berenberg initiates with a target price of 1600p and a buy recommendation.Hikma Pharmaceuticals: Jefferies moves target price from 1600p to 1610p and keeps a hold recommendation.IMI: Investec places its target price (prev.: 1570p) under review, while leaving its buy recommendation unchanged.Informa: Goldman Sachs ups target price from 527p to 550p upgrading from sell to neutral.Intu Properties: Deutsche Bank moves target price from 270p to 280p and maintains a hold recommendation.Lancashire Holdings: Credit Suisse reduces target price from 800p to 680p, while leaving its outperform rating unaltered.Lloyds Banking Group: Deutsche Bank shifts target price from 87p to 89p and keeps a buy recommendation.Man Group: Panmure Gordon downgrades from buy to hold with a target price of 125p.Micro Focus: Jefferies raises target price from 420p to 635p, while maintaining an underperform rating.Next: Berenberg raises target price from 7740p to 8075p maintaining a buy recommendation.Parkmead: Numis initiates with a target price of 262p and a buy recommendation.Pennon Group: Credit Suisse moves target price from 645p to 655p and reiterates an underperform rating.PZ Cussons: Panmure Gordon moves target price from 400p to 410p retaining a buy recommendation.Randgold Resources: UBS downgrades from buy to neutral with a target price of 5400p. RBC Capital reduces target price from 5300p to 5200p and stays with a neutral rating.Rightmove: Jefferies reduces target price from 2260p to 2177p keeping a hold recommendation.Rolls-Royce Group: Deutsche Bank cuts target price from 900p to 860p retaining its sell recommendation.Royal Bank of Scotland: Investec ups target price from 325p to 340p, while downgrading from hold to sell.Royal Dutch Shell: Jefferies increases target price from 2460p to 2730p upgrading from hold to buy. UBS raises target price from 2300p to 2450p staying with its neutral rating.RPS Group: Jefferies reduces target price from 385p to 320p, while leaving its buy recommendation unchanged.Schroders: Jefferies raises target price from 2300p to 2500p and reiterates a hold recommendation. Numis cuts target price from 3087p to 3042p retaining its buy recommendation.SDL: Jefferies reduces target price from 620p to 480p, while keeping a buy recommendation.Severn Trent: Credit Suisse increases target price from 1540p to 1730p upgrading to neutral.Smith & Nephew: Investec downgrades from buy to add with a target price of 1100p.UBM: Canaccord Genuity cuts target price from 725p to 680p and retains a hold recommendation.United Utilities: Credit Suisse raises target price from 680p to 730p, while downgrading to underperform.Vesuvius: Investec places both its target price (prev.: 465p) and its add rating under review.Weir Group: Morgan Stanley raises target price from 2440p to 2510p and keeps an equal-weight rating.Zoopla Property: Jefferies initiates with a target price of 325p and a buy recommendation.
More News
22 Feb 2023 21:50

Hikma accuses Amarin of suppressing generic versions of heart pill

Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals

*

Read more
16 Feb 2023 15:49

UK earnings, trading statements calendar - next 7 days

Friday 17 February 
Allianz Technology Trust PLCFull Year Results
Kingspan Group PLCFull Year Results
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
Monday 20 February 
Bank of Cyprus Holdings PLCFull Year Results
Georgia Capital PLCFull Year Results
Goldplat PLCFull Year Results (TBC)
LungLife AI IncFull Year Results
Tristel PLCHalf Year Results
Wilmington PLCHalf Year Results
Tuesday 21 February 
Antofagasta PLCFull Year Results
BHP Group LtdHalf Year Results
Blancco Technology Group PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
HSBC Holdings PLCFull Year Results
InterContinental Hotels Group PLCFull Year Results
Safestore Holdings PLCTrading Statement
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Trifast PLCTrading Statement
Wednesday 22 February 
Avingtrans PLCHalf Year Results
City of London Investment Group PLCHalf Year Results
Conduit Holdings LtdFull Year Results
Liberty Global PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Primary Health Properties PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
Rio Tinto PLCFull Year Results
Synectics PLCFull Year Results
TBC Bank Group PLCFull Year Results
Transense Technologies PLCHalf Year Results
Thursday 23 February 
Anglo American PLCFull Year Results
Arbuthnot Banking Group PLCTrading Statement
BAE Systems PLCFull Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Drax Group PLCFull Year Results
Driver Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Made Tech Group PLCHalf Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
Versarien PLCFull Year Results
WPP PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
25 Jan 2023 09:33

LONDON BROKER RATINGS: Goldman likes UK banks; HSBC cuts Dr Martens

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
18 Jan 2023 15:07

Director dealings: Hikma Pharmaceuticals director snaps up shares

(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.

Read more
12 Jan 2023 17:55

Arecor transfers AT307 drug to Hikma for development, regains AT282

(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.

Read more
3 Jan 2023 17:31

FTSE 100 ends first trading day of 2023 on upbeat note

FTSE 100 up 1.4%, FTSE 250 adds 1.5%

*

Read more
3 Jan 2023 09:25

Hikma launches version of Xyrem medicine in US for treating narcolepsy

(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.

Read more
3 Jan 2023 09:24

LONDON BROKER RATINGS: Citigroup cuts Wizz Air; Redburn likes CRH

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:

Read more
3 Jan 2023 09:03

LONDON MARKET OPEN: Stocks jump in first session of 2023

(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.

Read more
3 Jan 2023 07:58

LONDON BRIEFING: Stocks called higher; China factory sector shrinks

(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.

Read more
3 Jan 2023 07:46

Hikma launches generic narcolepsy solution in US

(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.

Read more
8 Dec 2022 09:48

LONDON BROKER RATINGS: JPMorgan cuts Travis Perkins; BofA likes IAG

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
6 Dec 2022 10:48

RBC Capital Markets starts Hikma at 'outperform'

(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.

Read more
6 Dec 2022 10:26

LONDON BROKER RATINGS: JPMorgan cuts Lloyds but raises Barclays

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
15 Nov 2022 12:10

Credit Suisse initiates coverage of Hikma at 'outperform'

(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.